Safety issues force Novo Nordisk to shutter PhIII hemophilia trials
Five months after rolling out proof-of-concept data on their anti-tissue factor pathway inhibitor concizumab, Novo Nordisk abruptly shut down a trio of advanced clinical trials in the wake of serious safety issues.
The pharma company slammed the brakes on the three trials involving hemophilia A and B patients — 2 Phase IIIs and 1 Phase II — regardless of inhibitor status after 3 patients in the pivotal program experienced non-fatal thrombotic events, or blood clots.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.